Cherny NI, et al. - This investigation was aimed at gaining better understanding of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) and the ASCO Value Framework Net Health Benefit score version 2 (ASCO-NHB v2) for evaluating clinical benefit attributable to new therapies. For this purpose, the concordance between the frameworks was assessed by using ASCO-NHB v2 to score 102 randomized controlled trials in the noncurative setting already evaluated in the field testing of ESMO-MCBS v1.1. Researchers assessed studies with discordant scoring. A higher agreement between the frameworks was observed, compared to that observed in other studies that sought to compare them. The factors that predominantly contributed to discordance included different approaches to evaluation of relative and absolute gain for overall survival and progression-free survival, crediting tail of the curve gains, and assessing toxicity.